We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Prime Medicine has raised a total of $315m in Series A and B funding rounds to launch the company that will offer new gene-editing technology Prime Editing for developing cures for various diseases.